论文部分内容阅读
目的探讨大肠癌患者血清 TGFβ1水平与外周血 T 细胞亚群、NK 细胞活性的相关性及临床意义.方法 50例经病理证实的大肠癌,用 ELISA 法检测血清TGFβ1水平,用 SAP 法检测 T 细胞亚群,用 LDH 释放法检测NK 细胞活性;分析 TGFβ1与 T 细胞亚群、NK 细胞活性的相关性及其临床意义.结果大肠癌患者血清 TGFβ1水平为40.4±17.6(μg.L~(-1)),高于对照组的19.2±7.9(μg.L~(-1))(P<0.05);CD8~+细胞明显高于正常对照组45.3±9.9(%)vs32.2±7.8(%),P<0.05;CD3~+和 CD4~+细胞、CD4~+/CD8~+比值、NK 细胞活性明显低于正常对照组,分别是46.2±8.6(%)vs61.3±9.5(%),36.4±7.6(%)vs47.3±6.9(%),1.2±0.3vs1.7±0.4,24.6±6.6(%)vs31.3±7.1(%),P<0.05.Ⅲ、Ⅳ期大肠癌患者血清TGFβ1水平、CD8~+细胞明显高于Ⅰ、Ⅱ期患者,分别是50.5±16.1(μg.L~(-1))vs34.3±9.8(μg.L~(-1)),49.7±9.1(%)vs38.4±9.8(%)(P<0.05);CD3~+和 CD4~+细胞、CD4~/CD8~+比值、NK 细胞活性明显低于Ⅰ、Ⅱ期患者,分别是37.2±9.2(%)vs49.6±8.4(%),28.5±8.3(%)vs42.3±6.7(%),0.6±0.4vs1.5±0.2,16.2±5.9(%)vs28.3±7.8(%)(P<0.05);TGFβ1与CD3~+细胞、CD4~+细胞、CD4~+/CD8~+比值、NK 细胞活性呈负相关,与 CD8~+细胞呈正相关.结论 TGFβ1通过抑制患者的免疫功能而促进肿瘤的发生发展、漫润转移,检测血清 TGFβ1的水平可为临床治疗提供参考.
Objective To investigate the correlation and clinical significance of serum TGFβ1 levels in peripheral blood T lymphocyte subsets and NK cell activity in patients with colorectal cancer. Methods 50 cases of pathologically confirmed colorectal cancer were examined for serum TGFβ1 levels by ELISA and T cells were detected by SAP. In subgroups, the activity of NK cells was measured by LDH release assay; the correlation between TGFβ1 and T cell subsets and NK cell activity was analyzed. The results showed that serum TGFβ1 level was 40.4±17.6 (μg.L~(-1)) in patients with colorectal cancer. )), higher than the control group 19.2 ± 7.9 (μg.L -1) (P <0.05); CD8 ~ + cells was significantly higher than the normal control group 45.3 ± 9.9 (%) vs32.2 ± 7.8 (% ), P<0.05; CD3~+ and CD4~+ cells, CD4~+/CD8~+ ratio, and NK cell activity were significantly lower than the normal control group, which was 46.2±8.6(%) vs61.3±9.5(%), respectively. , 36.4±7.6 (%) vs47.3±6.9 (%), 1.2±0.3 vs 1.7±0.4, 24.6±6.6 (%) vs 31.3±7.1 (%), P<0.05.III, stage IV colorectal cancer The serum levels of TGFβ1 and CD8~+ cells in patients were significantly higher than those in stage I and II, which were 50.5±16.1 (μg.L~(-1)) vs34.3±9.8 (μg.L~(-1)), 49.7. ±9.1 (%) vs38.4±9.8 (%) (P<0.05); CD3~+ and CD4~+ cells, CD4~/CD8~+ ratio, and NK cell activity were significantly lower than those of phase I and II. Those were 37.2±9.2(%) vs49.6±8.4(%), 28.5±8.3(%) vs42.3±6.7(%), 0.6±0.4 vs1.5±0.2, 16.2±5.9(%) vs28, respectively. (3 ± 7.8 (%) (P <0.05); TGFβ1 was negatively correlated with CD3 + cells, CD4 + cells, CD4 + CD8 + ratio, NK cell activity, and positively correlated with CD8 + cells. TGFβ1 promotes the occurrence, development, and metastasis of tumors by inhibiting the immune function of patients. Detection of serum TGFβ1 levels can provide reference for clinical treatment.